Peluntamig (PT217)

PreclinicalSmall molecule

Peluntamig (PT217) is one of 13 small molecule programs targeting Small Cell Lung Cancer ( SCLC ). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Small Cell Lung Cancer ( SCLC )Recruiting

Small Cell Lung Cancer ( SCLC )Preclinical

Recruiting

Competition

Competitive Landscape

15 competitors in Small Cell Lung Cancer ( SCLC )

#DrugCompanyPhaseTrials

Tecentriq

Roche

Phase 3

4 2

Imfinzi

AstraZeneca

Phase 2

2 3

Trodelvy

Gilead

Phase 2

1 4

TRODELVY

Gilead

Phase 2

1 5

Tarlatamab-Dznl

Amgen

Phase 2

1 6

Venclexta

AbbVie

Phase 1

1 7

Taxol

Teva

Preclinical

2 8

Zepzelca

Jazz Pharmaceuticals

Preclinical

1 9

Camptosar

Pfizer

Preclinical

1 10

Hycamtin

MMeitheal

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Small Cell Lung Cancer ( SCLC )

NCT05652686

Clinical

Trials by Indication[1]

Small Cell Lung Cancer ( SCLC )1 trial

An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)

Recruiting·PPhanes Therapeutics·Preclinical·NCT05652686·203 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Peluntamig (PT217). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Peluntamig (PT217) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Peluntamig (PT217). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Phanes Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPhanes Therapeutics

Peluntamig (PT217)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Small Cell Lung Cancer ( SCLC )1 trial

References

Drug Info

Quick Facts

Related News